Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Abd-Elsalam
 
NCT04353336
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
97/97 inconclusive
    Chen
     
    NCT04384380
    RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
    21/12 inconclusive
      NO COVID-19 (Lyngbakken)
       
      NCT04316377
      RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
      27/26 inconclusive
        RECOVERY
         
        NCT04381936
        RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
        1561/3155 safety concern
        • inconclusive 9 % increase in deaths,deaths (time to event analysis only),death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
        • statistically significant 14 % increase in death or ventilation with a moderate degree of certainty due to some concern in risk of bias
        SOLIDARITY (WHO study) HCQ
         
        NCT04315948
        RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
        947/906 inconclusive
        • inconclusive 19 % increase in deaths,deaths (time to event analysis only),death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias

        COVID-19 mild to moderate meta-analysis

        FACCT Trial
         
        NCT04392973
        RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
        125/129 inconclusive
        • inconclusive 15 % decrease in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
        Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine
         
        NCT04322123
        RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
        221/227 safety concern
        • statistically significant 74 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
        19 studies excluded by filtering options (16 RCT / 3 OBS)

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).